The company states: “ANI Pharmaceuticals announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Estradiol Gel, 0.1%. ANI’s Estradiol Gel, 0.1%, is the generic version of the Reference Listed Drug Divigel(R). The current annual U.S. market for Estradiol Gel, 0.1%, is approximately $42.3 million, according to IQVIA, a leading healthcare data and analytics provider.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANIP:
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
- ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
- ANI Pharmaceuticals price target raised to $73 from $60 at H.C. Wainwright
- ANI Pharmaceuticals CFO Carey sells 17,639 common shares